-DOCSTART- -X- O
Acute -X- _ O
respiratory -X- _ O
tract -X- _ O
infections -X- _ O
are -X- _ O
a -X- _ O
major -X- _ O
cause -X- _ O
of -X- _ O
respiratory -X- _ O
morbidity -X- _ O
and -X- _ O
mortality -X- _ O
in -X- _ O
pediatric -X- _ O
patients -X- _ O
worldwide. -X- _ O
However -X- _ O
, -X- _ O
accurate -X- _ O
viral -X- _ O
and -X- _ O
immunologic -X- _ O
markers -X- _ O
to -X- _ O
predict -X- _ O
clinical -X- _ O
outcomes -X- _ O
of -X- _ O
this -X- _ O
patient -X- _ O
population -X- _ O
are -X- _ O
still -X- _ O
lacking. -X- _ O
Droplet -X- _ B-Intervention
digital -X- _ I-Intervention
PCR -X- _ I-Intervention
assays -X- _ I-Intervention
for -X- _ O
influenza -X- _ B-Patient
and -X- _ I-Patient
respiratory -X- _ I-Patient
syncytial -X- _ I-Patient
virus -X- _ I-Patient
( -X- _ I-Patient
RSV -X- _ I-Patient
) -X- _ I-Patient
were -X- _ I-Patient
designed -X- _ I-Patient
and -X- _ I-Patient
performed -X- _ I-Patient
in -X- _ I-Patient
64 -X- _ I-Patient
respiratory -X- _ I-Patient
samples -X- _ I-Patient
from -X- _ I-Patient
23 -X- _ I-Patient
patients -X- _ I-Patient
with -X- _ I-Patient
influenza -X- _ I-Patient
virus -X- _ I-Patient
infection -X- _ I-Patient
and -X- _ I-Patient
73 -X- _ I-Patient
samples -X- _ I-Patient
from -X- _ I-Patient
19 -X- _ I-Patient
patients -X- _ I-Patient
with -X- _ I-Patient
RSV -X- _ I-Patient
infection. -X- _ I-Patient
Samples -X- _ O
of -X- _ O
patients -X- _ B-Patient
with -X- _ I-Patient
hematologic -X- _ I-Patient
malignancies -X- _ I-Patient
, -X- _ I-Patient
solid -X- _ I-Patient
tumors -X- _ I-Patient
, -X- _ I-Patient
or -X- _ I-Patient
sickle -X- _ I-Patient
cell -X- _ I-Patient
disease -X- _ I-Patient
were -X- _ I-Patient
included. -X- _ I-Patient
Clinical -X- _ O
information -X- _ O
from -X- _ O
institutional -X- _ O
medical -X- _ O
records -X- _ O
was -X- _ O
reviewed -X- _ O
to -X- _ O
assess -X- _ O
disease -X- _ O
severity. -X- _ O
Samples -X- _ O
from -X- _ O
patients -X- _ O
with -X- _ O
fever -X- _ O
or -X- _ O
respiratory -X- _ O
symptoms -X- _ O
had -X- _ O
a -X- _ O
significantly -X- _ O
higher -X- _ O
viral -X- _ O
loads -X- _ O
than -X- _ O
those -X- _ O
from -X- _ O
asymptomatic -X- _ O
patients. -X- _ O
Samples -X- _ B-Outcome
from -X- _ I-Outcome
patients -X- _ I-Outcome
with -X- _ I-Outcome
influenza -X- _ I-Outcome
virus -X- _ I-Outcome
and -X- _ I-Outcome
RSV -X- _ I-Outcome
infection -X- _ I-Outcome
collected -X- _ I-Outcome
at -X- _ I-Outcome
presentation -X- _ I-Outcome
had -X- _ I-Outcome
significantly -X- _ I-Outcome
higher -X- _ I-Outcome
viral -X- _ I-Outcome
loads -X- _ I-Outcome
than -X- _ I-Outcome
those -X- _ I-Outcome
collected -X- _ I-Outcome
from -X- _ I-Outcome
patients -X- _ I-Outcome
after -X- _ I-Outcome
completing -X- _ I-Outcome
a -X- _ I-Outcome
course -X- _ I-Outcome
of -X- _ I-Outcome
oseltamivir -X- _ I-Outcome
or -X- _ I-Outcome
ribavirin -X- _ I-Outcome
, -X- _ I-Outcome
respectively. -X- _ I-Outcome
RSV -X- _ I-Outcome
loads -X- _ I-Outcome
correlated -X- _ I-Outcome
positively -X- _ I-Outcome
with -X- _ I-Outcome
clinical -X- _ I-Outcome
symptoms -X- _ I-Outcome
in -X- _ I-Outcome
patients -X- _ I-Outcome
â‰¤5 -X- _ I-Outcome
years -X- _ I-Outcome
of -X- _ I-Outcome
age -X- _ I-Outcome
, -X- _ I-Outcome
whereas -X- _ I-Outcome
influenza -X- _ I-Outcome
viral -X- _ I-Outcome
loads -X- _ I-Outcome
were -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
clinical -X- _ I-Outcome
symptoms -X- _ I-Outcome
, -X- _ I-Outcome
irrespective -X- _ I-Outcome
of -X- _ I-Outcome
age. -X- _ I-Outcome
Patients -X- _ I-Outcome
receiving -X- _ I-Outcome
antivirals -X- _ I-Outcome
for -X- _ I-Outcome
influenza -X- _ I-Outcome
and -X- _ I-Outcome
RSV -X- _ I-Outcome
had -X- _ I-Outcome
a -X- _ I-Outcome
significant -X- _ I-Outcome
reduction -X- _ I-Outcome
in -X- _ I-Outcome
viral -X- _ I-Outcome
loads -X- _ I-Outcome
after -X- _ I-Outcome
completing -X- _ I-Outcome
therapy. -X- _ I-Outcome
Digital -X- _ O
PCR -X- _ O
offers -X- _ O
an -X- _ O
effective -X- _ O
method -X- _ O
to -X- _ O
monitor -X- _ O
the -X- _ O
efficacy -X- _ O
of -X- _ O
antiviral -X- _ O
treatment -X- _ O
for -X- _ O
respiratory -X- _ O
tract -X- _ O
infections -X- _ O
in -X- _ O
immunocompromised -X- _ O
hosts -X- _ O
. -X- _ O

